The OIG report reveals a 5% rise in Medicare Part B spending on lab tests, focusing on genetic testing compliance challenges and regulatory scrutiny in healthcare.

CMS's price-substitution policy has saved $76 million for Medicare by correcting drug pricing identified by the Office of Inspector General, improving cost efficiency while maintaining access.